DeepMed Research

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

Phase 2

Terminated

Conditions: Gastric Cancer
Esophageal Cancer
Gastric Adenocarcinoma

Interventions: Drug: Irinotecan
Drug: Cisplatin
Procedure: Surgery
Drug: Floxuridine
Drug: Capecitabine

First Posted Date: 2009-02-20

Last Posted Date: 2018-01-08

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00848783

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States
🇺🇸
Norris Cancer Center, Los Angeles, California, United States

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Doxil
Drug: Bevacizumab (Avastin)

First Posted Date: 2009-02-19

Last Posted Date: 2019-09-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 15

Registration Number: NCT00846612

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
Univ. of New Mexico cancer research and treatment center, Albuquerque, New Mexico, United States
🇺🇸
NYU medical center (Tisch Hospital), New York, New York, United States

and more 1 locations

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide (Revlimid)
Drug: Melphalan
Drug: Dexamethasone

First Posted Date: 2009-02-13

Last Posted Date: 2017-07-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00843310

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Tisch Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Gleevec/Paclitaxel

First Posted Date: 2009-02-10

Last Posted Date: 2012-11-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 14

Registration Number: NCT00840450

Locations: 🇺🇸
NYU cancer center, New York, New York, United States

Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Behavioral: Colorecatal Cancer Screening Activation

First Posted Date: 2009-02-04

Last Posted Date: 2009-02-04

Lead Sponsor: NYU Langone Health

Target Recruit Count: 130

Registration Number: NCT00836303

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Enoxaparin and/or Minocycline in Acute Stroke

Not Applicable

Terminated

Conditions: Acute Ischemic Stroke

Interventions: Drug: Enoxaparin
Drug: Minocycline

First Posted Date: 2009-02-04

Last Posted Date: 2016-04-29

Lead Sponsor: NYU Langone Health

Target Recruit Count: 6

Registration Number: NCT00836355

Locations: 🇺🇸
New York University Langone Medical Center, New York, New York, United States
🇺🇸
Bellevue Hospital Center, New York, New York, United States

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

Phase 4

Completed

Conditions: Postoperative Cognitive Dysfunction
Delirium

Interventions: Other: Placebo Patch
Drug: Rivastigmine Patch

First Posted Date: 2009-02-03

Last Posted Date: 2015-02-09

Lead Sponsor: NYU Langone Health

Target Recruit Count: 30

Registration Number: NCT00835159

Locations: 🇺🇸
NYU Langone Medical Center, Department of Anesthesiology 550 First Avenue, RR-603, New York, New York, United States

Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV

Not Applicable

Completed

Conditions: Peripheral Neuropathy
HIV
AIDS
HIV Infections

Interventions: Other: Acupuncture / Moxibustion
Other: Acupuncture/Moxibustion

First Posted Date: 2009-01-22

Last Posted Date: 2012-06-22

Lead Sponsor: NYU Langone Health

Target Recruit Count: 20

Registration Number: NCT00826345

Locations: 🇺🇸
Columbia University, New York, New York, United States

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Phase 2

Completed

Conditions: Focal Segmental Glomerulosclerosis

Interventions: Drug: Lisinopril, losartan, and atorvastatin
Drug: Adalimumab
Drug: galactose

First Posted Date: 2008-12-24

Last Posted Date: 2016-07-11

Lead Sponsor: NYU Langone Health

Target Recruit Count: 32

Registration Number: NCT00814255

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸
Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States

and more 15 locations

Carotid Ultrasound in the Evaluation of Heart Failure

Not Applicable

Completed

Conditions: Heart Failure
Coronary Artery Disease
Cardiomyopathy

Interventions: Other: Carotid ultrasound

First Posted Date: 2008-12-18

Last Posted Date: 2016-04-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 150

Registration Number: NCT00810550

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy